FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2561377204> ?p ?o ?g. }

• W2561377204 endingPage "S152" @default.
• W2561377204 startingPage "S152" @default.
• W2561377204 abstract "Pompe disease causes a progressive myopathy resulting from acid α-glucosidase (GAA) deficiency in the heart and skeletal muscle. Enzyme replacement therapy (ERT) with recombinant human (rh) GAA has prolonged the survival of patients. However, complete reversal neuromuscular involvement has not been possible in Pompe disease by treating with ERT. The paucity of cation-independent mannose-6-phosphate receptor (CI-MPR) in skeletal muscle, where it is needed to take up rhGAA, correlated with a poor response to ERT by muscle in Pompe disease. Clenbuterol, a selective β2 receptor agonist, enhanced the CI-MPR expression in striated muscle, and increased the efficacy of either ERT or gene therapy in murine Pompe disease. The underlying mechanism of clenbuterol's therapeutic action is Igf-1 mediated muscle hypertrophy, which has correlated with increased CI-MPR (also the Igf-2 receptor) expression. In this study we have evaluated 4 new drugs in GAA knockout (KO) mice in combination with an adeno-associated virus (AAV) vector encoding human GAA. The dosage for each drug was selected to induce muscle hypertrophy with an associated increased expression of CI-MPR, analogous to clenbuterol's effects. Three alternative β2 agonists and dehydroepiandrosterone (DHEA) were evaluated in combination with gene therapy in GAA-KO mice. Mice were transgenic for a liver-specific human GAA transgene to induce immune tolerance to introduced GAA. The 3 new β2 agonists were chosen to be long-acting like clenbuterol. Furthermore, DHEA caused muscle hypertrophy similar to the β2 agonists, is available in the US, and was well-tolerated in rodent experiments. Mice were injected with AAV2/9-CBhGAA (1E+11 vector particles) at a dose previously found to be partially effective at clearing glycogen storage from the the heart. Heart GAA activity was significantly increased by either salmeterol (p<0.01) or DHEA (p<0.05), in comparison with untreated mice. Furthermore, glycogen content was reduced by treatment with DHEA (p>0.001), salmeterol (p<0.05), formoterol (p<0.01), or clenbuterol (p<0.01) in combination with the AAV vector, in comparison with untreated mice. Functional testing was performed subsequently, and the wirehang test at 18 weeks following vector administration revealed that the combination of salmeterol and the AAV vector significantly increased latency in comparison with untreated mice (p<0.01), AAV vector alone (p<0.001). Similarly, salmeterol with the vector increased latency significantly more than either DHEA (p<0.001), formoterol (p<0.05), fenoterol (p<0.05), or clenbuterol (p<0.05) with the vector. An important consideration with regard to adjunctive therapy is whether any effects are due to the adjuvant rather than the combined treatment. The most effective individual drugs were evaluated by themselves, and no significant effect upon GAA activity of heart, glycogen content of heart, or wirehang latency was observed, in comparison with untreated mice. Thus, salmeterol should be further developed as adjunctive therapy in combination with either ERT or gene therapy for Pompe disease." @default.
• W2561377204 created "2017-01-06" @default.
• W2561377204 creator A5045419573 @default.
• W2561377204 creator A5055884753 @default.
• W2561377204 creator A5083173744 @default.
• W2561377204 date "2016-05-01" @default.
• W2561377204 modified "2023-09-24" @default.
• W2561377204 title "381. Prohypertrophic Agents Enhance the Response to Gene Therapy in Pompe Disease" @default.
• W2561377204 doi "https://doi.org/10.1016/s1525-0016(16)33190-2" @default.
• W2561377204 hasPublicationYear "2016" @default.
• W2561377204 type Work @default.
• W2561377204 sameAs 2561377204 @default.
• W2561377204 citedByCount "0" @default.
• W2561377204 crossrefType "journal-article" @default.
• W2561377204 hasAuthorship W2561377204A5045419573 @default.
• W2561377204 hasAuthorship W2561377204A5055884753 @default.
• W2561377204 hasAuthorship W2561377204A5083173744 @default.
• W2561377204 hasBestOaLocation W25613772041 @default.
• W2561377204 hasConcept C102230213 @default.
• W2561377204 hasConcept C104317684 @default.
• W2561377204 hasConcept C111599444 @default.
• W2561377204 hasConcept C126322002 @default.
• W2561377204 hasConcept C134018914 @default.
• W2561377204 hasConcept C141035611 @default.
• W2561377204 hasConcept C167414201 @default.
• W2561377204 hasConcept C170493617 @default.
• W2561377204 hasConcept C2776327530 @default.
• W2561377204 hasConcept C2777300911 @default.
• W2561377204 hasConcept C2778107364 @default.
• W2561377204 hasConcept C2778938600 @default.
• W2561377204 hasConcept C2779134260 @default.
• W2561377204 hasConcept C2779959927 @default.
• W2561377204 hasConcept C2779969927 @default.
• W2561377204 hasConcept C40767141 @default.
• W2561377204 hasConcept C55493867 @default.
• W2561377204 hasConcept C71924100 @default.
• W2561377204 hasConcept C86803240 @default.
• W2561377204 hasConcept C92087593 @default.
• W2561377204 hasConcept C98274493 @default.
• W2561377204 hasConceptScore W2561377204C102230213 @default.
• W2561377204 hasConceptScore W2561377204C104317684 @default.
• W2561377204 hasConceptScore W2561377204C111599444 @default.
• W2561377204 hasConceptScore W2561377204C126322002 @default.
• W2561377204 hasConceptScore W2561377204C134018914 @default.
• W2561377204 hasConceptScore W2561377204C141035611 @default.
• W2561377204 hasConceptScore W2561377204C167414201 @default.
• W2561377204 hasConceptScore W2561377204C170493617 @default.
• W2561377204 hasConceptScore W2561377204C2776327530 @default.
• W2561377204 hasConceptScore W2561377204C2777300911 @default.
• W2561377204 hasConceptScore W2561377204C2778107364 @default.
• W2561377204 hasConceptScore W2561377204C2778938600 @default.
• W2561377204 hasConceptScore W2561377204C2779134260 @default.
• W2561377204 hasConceptScore W2561377204C2779959927 @default.
• W2561377204 hasConceptScore W2561377204C2779969927 @default.
• W2561377204 hasConceptScore W2561377204C40767141 @default.
• W2561377204 hasConceptScore W2561377204C55493867 @default.
• W2561377204 hasConceptScore W2561377204C71924100 @default.
• W2561377204 hasConceptScore W2561377204C86803240 @default.
• W2561377204 hasConceptScore W2561377204C92087593 @default.
• W2561377204 hasConceptScore W2561377204C98274493 @default.
• W2561377204 hasLocation W25613772041 @default.
• W2561377204 hasOpenAccess W2561377204 @default.
• W2561377204 hasPrimaryLocation W25613772041 @default.
• W2561377204 hasRelatedWork W1779480512 @default.
• W2561377204 hasRelatedWork W2015970244 @default.
• W2561377204 hasRelatedWork W2018690794 @default.
• W2561377204 hasRelatedWork W2103288374 @default.
• W2561377204 hasRelatedWork W2104791454 @default.
• W2561377204 hasRelatedWork W2122395778 @default.
• W2561377204 hasRelatedWork W2550488380 @default.
• W2561377204 hasRelatedWork W2561377204 @default.
• W2561377204 hasRelatedWork W4246178386 @default.
• W2561377204 hasRelatedWork W4248381333 @default.
• W2561377204 hasVolume "24" @default.
• W2561377204 isParatext "false" @default.
• W2561377204 isRetracted "false" @default.
• W2561377204 magId "2561377204" @default.
• W2561377204 workType "article" @default.